Assertio Holdings Inc
ASRT0.720USD
+0.007+1.04%
Horário de mercado （ET）Cotações atrasadas em 15 min
68.95MValor de mercado
PerdaP/L TTM
Mais detalhes de Assertio Holdings Inc Empresa
Assertio Holdings, Inc. is a commercial pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through acquisition or licensing of approved products. Its comprehensive commercial capabilities include marketing through both a sales force and a non-personal promotion model, market access through payor contracting and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, CAMBIA (diclofenac potassium for oral solution) and Zipsor (diclofenac potassium) Liquid filled capsules. INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID).
Informações da empresa
Código da empresaASRT
Nome da EmpresaAssertio Holdings Inc
Data de listagemFeb 12, 1997
CEOMr. Brendan P. O'Grady
Número de funcionários58
Tipo de títulosOrdinary Share
Fim do ano fiscalFeb 12
Endereço100 S. Saunders Road
CidadeLAKE FOREST
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal60045
Telefone12244197106
Sitehttps://www.assertiotx.com/
Código da empresaASRT
Data de listagemFeb 12, 1997
CEOMr. Brendan P. O'Grady
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Ajay Patel
Mr. Ajay Patel
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
196.85K
+12.05%
Mr. Paul Schwichtenberg
Mr. Paul Schwichtenberg
Executive Vice President, Chief Transformation Officer
Executive Vice President, Chief Transformation Officer
167.52K
+14.47%
Mr. Sam Schlessinger
Mr. Sam Schlessinger
Executive Vice President, General Counsel
Executive Vice President, General Counsel
156.13K
+17.33%
Mr. Brendan P. O'Grady
Mr. Brendan P. O'Grady
Chief Executive Officer, Director
Chief Executive Officer, Director
128.96K
+1001.61%
Mr. David Matthew Stark
Mr. David Matthew Stark
Independent Director
Independent Director
107.50K
+100.00%
Mr. William T. Mckee
Mr. William T. Mckee
Independent Director
Independent Director
97.28K
+123.48%
Mr. Mark L Reisenauer
Mr. Mark L Reisenauer
Independent Director
Independent Director
53.75K
--
Ms. Heather L. Mason
Ms. Heather L. Mason
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Sigurd C. (Sig) Kirk
Mr. Sigurd C. (Sig) Kirk
Independent Director
Independent Director
--
--
Mr. Sravan K. Emany
Mr. Sravan K. Emany
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Ajay Patel
Mr. Ajay Patel
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
196.85K
+12.05%
Mr. Paul Schwichtenberg
Mr. Paul Schwichtenberg
Executive Vice President, Chief Transformation Officer
Executive Vice President, Chief Transformation Officer
167.52K
+14.47%
Mr. Sam Schlessinger
Mr. Sam Schlessinger
Executive Vice President, General Counsel
Executive Vice President, General Counsel
156.13K
+17.33%
Mr. Brendan P. O'Grady
Mr. Brendan P. O'Grady
Chief Executive Officer, Director
Chief Executive Officer, Director
128.96K
+1001.61%
Mr. David Matthew Stark
Mr. David Matthew Stark
Independent Director
Independent Director
107.50K
+100.00%
Mr. William T. Mckee
Mr. William T. Mckee
Independent Director
Independent Director
97.28K
+123.48%
Detalhamento da receita
Moeda: USDAtualizado em: dom, 6 de jul
Moeda: USDAtualizado em: dom, 6 de jul
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Por EmpresaUSD
Nome
Receita
Proporção
ROLVEDON
13.12M
49.54%
INDOCIN products
5.54M
20.93%
other
3.56M
13.44%
Sympazan
2.18M
8.23%
SPRIX Nasal Spray
1.59M
6.00%
Royalties and milestone revenue
494.00K
1.86%
Por RegiãoUSD
Nome
Receita
Proporção
United States
26.49M
100.00%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
ROLVEDON
13.12M
49.54%
INDOCIN products
5.54M
20.93%
other
3.56M
13.44%
Sympazan
2.18M
8.23%
SPRIX Nasal Spray
1.59M
6.00%
Royalties and milestone revenue
494.00K
1.86%
Distribuição de ações
Atualizado em: sex, 16 de mai
Atualizado em: sex, 16 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Nantahala Capital Management, LLC
8.81%
The Vanguard Group, Inc.
4.58%
Renaissance Technologies LLC
2.82%
BlackRock Institutional Trust Company, N.A.
1.45%
Two Sigma Investments, LP
1.28%
Other
81.06%
Investidores
Investidores
Proporção
Nantahala Capital Management, LLC
8.81%
The Vanguard Group, Inc.
4.58%
Renaissance Technologies LLC
2.82%
BlackRock Institutional Trust Company, N.A.
1.45%
Two Sigma Investments, LP
1.28%
Other
81.06%
Tipos de investidores
Investidores
Proporção
Hedge Fund
13.93%
Investment Advisor
9.29%
Investment Advisor/Hedge Fund
3.63%
Individual Investor
2.63%
Research Firm
0.15%
Other
70.37%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
311
28.39M
29.65%
-30.82M
2025Q1
337
28.16M
29.40%
-32.55M
2024Q4
339
31.00M
32.47%
-30.41M
2024Q3
330
33.06M
34.86%
-33.72M
2024Q2
326
40.98M
43.17%
-33.17M
2024Q1
316
48.96M
52.78%
-20.37M
2023Q4
308
49.49M
53.68%
-10.26M
2023Q3
295
49.25M
53.86%
+8.83M
2023Q2
258
36.71M
65.25%
+1.46M
2023Q1
203
27.95M
50.57%
+2.57M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Nantahala Capital Management, LLC
8.44M
8.81%
+291.43K
+3.58%
Mar 31, 2025
The Vanguard Group, Inc.
4.38M
4.58%
--
--
Mar 31, 2025
Renaissance Technologies LLC
2.70M
2.82%
-289.05K
-9.66%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.39M
1.45%
-13.17K
-0.94%
Mar 31, 2025
Two Sigma Investments, LP
1.23M
1.28%
-401.09K
-24.66%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.11M
1.16%
+11.78K
+1.08%
Mar 31, 2025
Millennium Management LLC
784.58K
0.82%
-316.70K
-28.76%
Mar 31, 2025
Polen Capital Management, LLC
424.06K
0.44%
-227.56K
-34.92%
Nov 30, 2024
AQR Capital Management, LLC
636.77K
0.66%
-265.80K
-29.45%
Mar 31, 2025
Peisert (Daniel A)
607.46K
0.63%
--
--
Mar 13, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
Invesco RAFI US 1500 Small-Mid ETF
0.01%
Franklin US Small Cap Multifactor Index ETF
0%
ALPS Barron's 400 ETF
0%
iShares Russell 2000 Value ETF
0%
iShares Russell 2000 ETF
0%
Avantis Responsible US Equity ETF
0%
Global X Russell 2000 ETF
0%
Royce Quant Small-Cap Quality Value ETF
0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0%
Avantis US Small Cap Equity ETF
0%
Ver Mais
Invesco RAFI US 1500 Small-Mid ETF
Proporção0.01%
Franklin US Small Cap Multifactor Index ETF
Proporção0%
ALPS Barron's 400 ETF
Proporção0%
iShares Russell 2000 Value ETF
Proporção0%
iShares Russell 2000 ETF
Proporção0%
Avantis Responsible US Equity ETF
Proporção0%
Global X Russell 2000 ETF
Proporção0%
Royce Quant Small-Cap Quality Value ETF
Proporção0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proporção0%
Avantis US Small Cap Equity ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
May 17, 2021
Merger
4<1
May 17, 2021
Merger
4<1
May 17, 2021
Merger
4<1
May 17, 2021
Merger
4<1
Data
Tipo
Proporção
May 17, 2021
Merger
4<1
May 17, 2021
Merger
4<1
May 17, 2021
Merger
4<1
May 17, 2021
Merger
4<1
